Drugs for Penile Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 70)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Irinotecan |
Approved, Investigational |
Phase 2 |
|
97682-44-5, 100286-90-6 |
60838 |
Synonyms:
(+)-Irinotecan
7 Ethyl 10 hydroxycamptothecin
7-Ethyl-10-hydroxycamptothecin
Biotecan
Camptosar
Camptothecin 11
Camptothecin-11
CP0
CPT 11
CPT11
CPT-11
HSDB 7607
Irinophore C
IRINOTECAN
|
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
NK012 Compound
sn 38
sn-38
sn38 CPD
|
|
2 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
3 |
|
Avelumab |
Approved, Investigational |
Phase 2 |
|
1537032-82-8 |
|
Synonyms:
AVELUMAB
BAVENCIO
MSB0010682
|
|
|
4 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
5 |
|
Fluorouracil |
Approved |
Phase 2 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
6 |
|
Niraparib |
Approved, Investigational |
Phase 2 |
|
1038915-60-4 |
24958200 |
Synonyms:
COMPOUND 56 [PMID 19873981]
compound 56 [PMID 19873981]|MK 4827|MK-4827|Zejula®
JNJ-64091742
MK 4827
|
MK4827
MK-4827
NIRAPARIB
ZL-2306
|
|
7 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
8 |
|
Atezolizumab |
Approved, Investigational |
Phase 2 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
9 |
|
Vorinostat |
Approved, Investigational |
Phase 2 |
|
149647-78-9 |
5311 |
Synonyms:
18F Suberoylanilide hydroxamic acid
18F-SAHA
18F-Suberoylanilide hydroxamic acid
Merck brand OF vorinostat
MK0683
MK-0683
MK-0683|MK0683|SAHA|suberoylanilide hydroxamic acid|Zolinza®
N Hydroxy n' phenyloctanediamide
N1 Hydroxy N8 phenyloctanediamide
N1-Hydroxy-N8-phenyloctanediamide
NHNPODA
N-Hydroxy-n'-phenyloctanediamide
N-Hyrdroxy-n'-phenyloctanediamide
|
Octanedioate hydroxyamide phenylamide
Octanedioic acid hydroxyamide phenylamide
SAHA
SHH
Suberanilohydroxamate
Suberanilohydroxamic acid
Suberoyl anilide hydroxamic acid
Suberoylanilide hydroxamate
Suberoylanilide hydroxamic acid
VORINOSTAT
Vorinostatum
Zolinza
|
|
10 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
11 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
12 |
|
Fludarabine |
Approved |
Phase 1, Phase 2 |
|
75607-67-9, 21679-14-1 |
30751 657237 |
Synonyms:
2-F-ARAA
2-F-Ara-A|CCRIS 3382|F-Ara-A|Fludara®
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-Fluoro-ara AMP
2-FLUORO-ARA-A
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-Β-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-Β-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
|
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
Beneflur
FAMP
FaraAMP
F-Ara-AMP
Fludara
Fludarabina
FLUDARABINE
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabine phosphoric acid
Fludarabinum
Fludura
Fluoro-ara-AMP
NSC-312887
NSC-328002
OFORTA
|
|
13 |
|
Aldesleukin |
Approved |
Phase 1, Phase 2 |
|
110942-02-4 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Aldesleukin
Aldesleukina
IL-2
ILT101
ILT-101
Interleukin-2 aldesleukin
|
INTERLEUKIN-2 PRECURSOR
Interleukin-2(2-133),125-ser
Recombinant human interleukin-2
Recombinant interleukin-2 human
T-CELL GROWTH FACTOR
TCGF
|
|
14 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 1, Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
15 |
|
Docetaxel |
Approved, Investigational |
Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
16 |
|
Isotretinoin |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
302-79-4, 4759-48-2 |
5538 444795 5282379 |
Synonyms:
(13-cis)-Retinoate
(13-CIS)-RETINOIC ACID
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXENYL)NONA-2,4,6,8-TETRAENOIC ACID
(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate
(2Z,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAENOIC ACID
(7E,9E,11E,13Z)-Retinoate
(7E,9E,11E,13Z)-RETINOIC ACID
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
13 cis Retinoic acid
13 CIS-RETINOIC ACID
13-cis-Retinoate
13-cis-Retinoate,isotretinoin
13-CIS-RETINOIC ACID
13-CIS-VITAMIN A ACID
13-RA
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoate (ecl)
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
Aberel
ABSORICA
ACCUTANE
Acid, all-trans-retinoic
Acid, beta-all-trans-retinoic
Acid, retinoic
Acid, trans-retinoic
Acid, vitamin a
Acide retinoique
ACIDE RETINOIQUE (FRENCH)
ACIDE RETINOIQUE (FRENCH) (DSL)
ACTICIN
AGN 100335
Airol
Aknefug
Aknoten
all trans Retinoic acid
all trans-Retinoic acid
all-(e)-Retinoate
all-(e)-Retinoic acid
all-trans-beta-Retinoate
all-trans-beta-Retinoic acid
all-trans-b-Retinoate
all-trans-b-Retinoic acid
all-trans-Retinoate
all-trans-Retinoic acid
ALL-TRANS-RETINOIC ACID (ATRA)
all-trans-retinoic acid (ATRA)|Altreno® (0.05% lotion)|Avita® (0.025% gel)|Renova® (0.02% cream)
all-trans-Tretinoin
all-trans-Vitamin a acid
all-trans-Vitamin a1 acid
all-trans-Β-retinoate
all-trans-Β-retinoic acid
ALTRENO
AMNESTEEM
ATRA
Atra-IV
Atralin
Avita
beta all trans Retinoic acid
beta-all-trans-Retinoic acid
beta-Retinoate
beta-Retinoic acid
b-Retinoate
b-Retinoic acid
CIP-isotretinoin
CIS-RA
cis-Retinoate
|
CIS-RETINOIC ACID
CLARAVIS
Dermairol
Eudyna
ISOTRETINOIN
Isotretinoin zinc salt, 13 cis isomer
Isotretinoin zinc salt, 13-cis-isomer
Isotretinoina
Isotretinoína
Isotretinoine
Isotrétinoine
Isotretinoino
Isotretinoinum
ISOTREX
Lsotretinoin
MYORISAN
NEOVITAMIN A ACID
NSC-122758
PAT-001
Potassium salt, tretinoin
Renova
Retin a
Retin-a
Retin-a micro
RETIN-A-MICRO
Retinoate
Retinoic acid
RETINOIC ACID 13-CIS-FORM
Retionic acid
Retisol-a
Ro 1-5488
RO-43780
RO-4-3780
Roaccutan
ROACCUTANE
Roacutan
Salt, tretinoin potassium
Salt, tretinoin sodium
Salt, tretinoin zinc
Sodium salt, tretinoin
Solage
SOTRET
Stieva-a
Stieva-a Forte
Teriosal
trans Retinoic acid
trans-Retinoate
trans-Retinoic acid
Tretin m
Tretinoin
Tretinoin potassium salt
Tretinoin sodium salt
Tretinoin zinc salt
TRETINOIN、ATRA
Tretinoina
Trétinoïne
TRETINOINE (FRENCH)
TRETINOINE (FRENCH) (EINECS)
Tretinoinum
Tretin-X
Tri-Luma
Vesanoid
Vitamin a acid
Vitinoin
ZENATANE
Zinc salt, tretinoin
Β-retinoate
Β-retinoic acid
|
|
17 |
|
Nimotuzumab |
Investigational |
Phase 2 |
|
780758-10-3 |
|
Synonyms:
HR3
NIMOTUZUMAB
THERACIM-HR3
|
THERALOC
THERALOC THERACIM
|
|
18 |
|
Entinostat |
Investigational |
Phase 1, Phase 2 |
|
209783-80-2 |
4261 |
Synonyms:
BAY 86-5274
BAY 86-5274|MS-275|SNDX-275|ZK 244894
BAY86-5274
ENTINOSTAT
Entinostatum
MS 27-275
MS 275
MS-27-275
|
MS-275
MS-275-27
N-(2-Aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide
N-[[4-[(2-Aminoanilino)-oxomethyl]phenyl]methyl]carbamate 3-pyridinylmethyl ester
N-[[4-[(2-Aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester
SNDX 275
SNDX-275
SNDX-275MS-275SID29217590
|
|
19 |
|
topoisomerase I inhibitors |
|
Phase 2 |
|
|
|
20 |
|
interferons |
|
Phase 2 |
|
|
|
21 |
|
Interferon-alpha |
|
Phase 2 |
|
|
|
22 |
|
Interferon-alfa-1b |
|
Phase 2 |
|
|
|
23 |
|
Dermatologic Agents |
|
Phase 2 |
|
|
|
24 |
|
Cola |
|
Phase 1, Phase 2 |
|
|
|
25 |
|
Poly(ADP-ribose) Polymerase Inhibitors |
|
Phase 2 |
|
|
|
26 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
27 |
|
Immune Checkpoint Inhibitors |
|
Phase 2 |
|
|
|
28 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
29 |
|
Antibodies |
|
Phase 2 |
|
|
|
30 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
31 |
|
Histone Deacetylase Inhibitors |
|
Phase 2 |
|
|
|
32 |
|
Interleukin-12 |
|
Phase 2 |
|
|
|
33 |
|
Immunoglobulins, Intravenous |
|
Phase 2 |
|
|
|
34 |
|
Adjuvants, Immunologic |
|
Phase 2 |
|
|
|
35 |
|
Immunoglobulin G |
|
Phase 2 |
|
|
|
36 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
37 |
|
Antiviral Agents |
|
Phase 1, Phase 2 |
|
|
|
38 |
|
Anti-Infective Agents |
|
Phase 1, Phase 2 |
|
|
|
39 |
|
Anti-Retroviral Agents |
|
Phase 1, Phase 2 |
|
|
|
40 |
|
Anti-HIV Agents |
|
Phase 1, Phase 2 |
|
|
|
41 |
|
Antimitotic Agents |
|
Phase 2 |
|
|
|
42 |
|
Tubulin Modulators |
|
Phase 2 |
|
|
|
43 |
|
Gemcitabine |
Approved |
Phase 1 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
44 |
|
Ganciclovir |
Approved, Investigational |
Phase 1 |
|
82410-32-0 |
3454 |
Synonyms:
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-Amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-Amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-propoxymethane)guanine
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
BIOLF-62
BW-759U
CYMEVENE
|
Cytovene
GA2
GANCICLOVIR
Ganciclovir sodium
Ganciclovir, monosodium salt
Ganciclovirum
Gancyclovir
RS-21592
VIRGAN
Vitrasert
Zirgan
|
|
45 |
|
Antimetabolites |
|
Phase 1 |
|
|
|
46 |
|
Ganciclovir triphosphate |
|
Phase 1 |
|
|
|
47 |
|
Immunosuppressive Agents |
|
Phase 1 |
|
|
|
48 |
|
Alkylating Agents |
|
Phase 1 |
|
|
|
49 |
|
Antineoplastic Agents, Alkylating |
|
Phase 1 |
|
|
|
50 |
|
Antirheumatic Agents |
|
Phase 1 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 55)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Phase II Study of (Neoadjuvant Chemotherapy Trial Prior to Extirpative Surgery) for Clinical Stage TanyN2-3M0 Squamous Cell Carcinoma of the Penis |
Completed |
NCT00512096 |
Phase 2 |
Ifosfamide;Paclitaxel (Taxol);Cisplatin |
2 |
A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers |
Completed |
NCT02280811 |
Phase 1, Phase 2 |
Fludarabine;Cyclophosphamide;Aldesleukin |
3 |
Phase II Study of Irinotecan (CPT 11) and Cisplatin (CDDP) in Metastatic or Locally Advanced Penile Carcinoma |
Completed |
NCT00066391 |
Phase 2 |
cisplatin;irinotecan hydrochloride |
4 |
ALPHA INTERFERON AND CIS-RETINOIC ACID FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMAS |
Completed |
NCT00002506 |
Phase 2 |
isotretinoin |
5 |
A Single Center and Single Arm Study of TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer |
Completed |
NCT04475016 |
Phase 2 |
Albumin-Bound Paclitaxel;Ifosfamide;Cisplatin;Nimotuzumab;Triprilimab |
6 |
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers |
Completed |
NCT01585428 |
Phase 2 |
Fludarabine;Cyclophosphamide;Aldesleukin |
7 |
AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males |
Completed |
NCT01209325 |
Phase 2 |
|
8 |
A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis |
Completed |
NCT02057913 |
Phase 2 |
Vinflunine |
9 |
Phase II Study of the Pan-HER Inhibitor Dacomitinib (PF-00299804) for Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis. |
Completed |
NCT01728233 |
Phase 2 |
Dacomitinib |
10 |
A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis |
Completed |
NCT03114254 |
Phase 2 |
Cabazitaxel |
11 |
A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors |
Recruiting |
NCT03333616 |
Phase 2 |
Ipilimumab;Nivolumab |
12 |
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers |
Recruiting |
NCT04708470 |
Phase 1, Phase 2 |
Bintrafusp Alfa;NHS-IL12;Entinostat |
13 |
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) |
Recruiting |
NCT03866382 |
Phase 2 |
Cabozantinib S-malate |
14 |
Activity and Tolerability of Maintenance Avelumab Immunotherapy After First Line Polychemotherapy Including Platinum in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma |
Recruiting |
NCT03774901 |
Phase 2 |
Avelumab |
15 |
A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based Chemotherapy |
Recruiting |
NCT03391479 |
Phase 2 |
Avelumab |
16 |
Prospective Phase II Study Evaluating a Multimodal Care of Inguinal Node Metastasis in Squamous Cell Carcinoma of the Penis by Bilateral Lymphadenectomy and Chemotherapy TIP |
Recruiting |
NCT02817958 |
Phase 2 |
Chemotherapy TIP |
17 |
A Phase II Trial of Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer: LACOG 0218 HERCULES Trial |
Recruiting |
NCT04224740 |
Phase 2 |
Pembrolizumab;Standard of care therapy |
18 |
A Phase 2 Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma Who Have Progressed Following Chemotherapy |
Recruiting |
NCT05526989 |
Phase 2 |
Dostarlimab;Niraparib |
19 |
A Single-arm, Open, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) in the Treatment of Urinary and Male Genital Tumors |
Recruiting |
NCT04718584 |
Phase 2 |
Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) |
20 |
Therapeutic HPV Vaccine Trial +/- Anti-CD40 in HPV-driven Squamous Cell Carcinoma |
Recruiting |
NCT03418480 |
Phase 1, Phase 2 |
BNT113 |
21 |
PERICLES (PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study)-a Phase 2 Study of Atezolizumab With or Without Radiotherapy in Penile Cancer |
Active, not recruiting |
NCT03686332 |
Phase 2 |
Arm A: Atezolizumab and Radiotherapy;Arm B: Atezolizumab |
22 |
Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma |
Active, not recruiting |
NCT04357873 |
Phase 2 |
pembrolizumab; vorinostat |
23 |
A Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of INCMGA00012 in Advanced Penile Squamous Cell Carcinoma. |
Active, not recruiting |
NCT04231981 |
Phase 2 |
INCMGA0012 |
24 |
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors |
Active, not recruiting |
NCT02721732 |
Phase 2 |
|
25 |
Phase II Trial of M7824 in Subjects With HPV Associated Malignancies |
Active, not recruiting |
NCT03427411 |
Phase 2 |
M7824 |
26 |
A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers |
Active, not recruiting |
NCT03439085 |
Phase 2 |
|
27 |
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types |
Active, not recruiting |
NCT03012581 |
Phase 2 |
Nivolumab |
28 |
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers |
Not yet recruiting |
NCT05639972 |
Phase 1, Phase 2 |
Conditioning, E7 TCR-T cells, and aldesleukin |
29 |
Phase II Study Of Weekly Docetaxel In Patients With Advanced Epidermoid Carcinoma Of The Penis |
Terminated |
NCT00058448 |
Phase 2 |
docetaxel |
30 |
Phase II Study With Pazopanib and Weekly Paclitaxel in Metastatic or Locally Advanced Squamous Penile Carcinoma Patients Previously Treated With Cisplatin Based Chemotherapy |
Terminated |
NCT02279576 |
Phase 2 |
Pazopanib;Paclitaxel |
31 |
A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma |
Withdrawn |
NCT02014831 |
Phase 2 |
Cetuximab;TIP |
32 |
VACCINE THERAPY AND DETECTION OF IMMUNOLOGIC RESPONSES WITH HUMAN PAPILLOMAVIRUS 16 E6 AND E7 PEPTIDES IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED CERVICAL CANCER |
Completed |
NCT00019110 |
Phase 1 |
|
33 |
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma |
Recruiting |
NCT04491942 |
Phase 1 |
Cisplatin;Elimusertib;Gemcitabine Hydrochloride |
34 |
Evaluate the Safety and Immunogenicity of the 9-valent Human Papillomavirus Recombinant Vaccine (Hansenula Polymorpha) in Chinese Male Aged 9-45 Years: A Randomized, Blinded and Placebo-Controlled Phase I Study |
Recruiting |
NCT05518201 |
Phase 1 |
|
35 |
Fluorescent Guided Surgery in Penile Carcinoma Using Cetuximab-800IRDyeCW |
Recruiting |
NCT05376202 |
Phase 1 |
Cetuximab-IRDye800CW |
36 |
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors |
Recruiting |
NCT04272034 |
Phase 1 |
INCB099318 |
37 |
An Open Multicenter Study of the Safety, Tolerability, and Pharmacokinetics of Different Doses of AntioncoRAN-M at Patients With Advanced-stage Solid Tumors With Cymeven® (Ganciclovir) Infusions |
Recruiting |
NCT05578820 |
Phase 1 |
|
38 |
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors |
Active, not recruiting |
NCT02496208 |
Phase 1 |
Cabozantinib S-malate |
39 |
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4) |
Active, not recruiting |
NCT03849469 |
Phase 1 |
|
40 |
HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers |
Active, not recruiting |
NCT02379520 |
Phase 1 |
Cytoxan;Fludarabine |
41 |
Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] |
Unknown status |
NCT02104063 |
|
|
42 |
Integrating a Health Information Technology System With a Web-based Mobile Health Educational Intervention to Support More Effective Provider-patient Communication and HPV Vaccine Utilization |
Completed |
NCT03346915 |
|
|
43 |
INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue |
Completed |
NCT04574427 |
|
|
44 |
A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination |
Completed |
NCT03856437 |
|
|
45 |
Videoscopic Versus Open Inguinal Lymphadenectomy for Sentinel Node Positive Cutaneous Malignancies and Genitourinary Staging Procedures |
Completed |
NCT01526486 |
|
|
46 |
Monocentric Study of Validation of the Method "CaptHPV" for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas From a Biological Specimen. |
Completed |
NCT02981862 |
|
|
47 |
Risk of Cancer in Patients Exposed to Gabapentin in the GPRD |
Completed |
NCT01236053 |
|
Gabapentin prescriptions |
48 |
Videoendoscopic Radical Inguinal Lymphadenectomy Versus Open Radical Inguinal Lymphadenectomy in Patients With Penile Cancer: a Feasibility Randomised Controlled Trial |
Recruiting |
NCT05592639 |
|
|
49 |
Development of Diagnostics and Treatment of Urological Cancers |
Recruiting |
NCT02994758 |
|
|
50 |
Integrated Cancer Repository for Cancer Research |
Recruiting |
NCT02012699 |
|
|
Cochrane evidence based reviews: penile neoplasms
|